Close menu




April 28th, 2020 | 07:13 CEST

Burcon Nutrascience, Enthusiast Gaming, EXMceuticals - Investing in the future

  • Investments
Photo credits: pixabay.com

Innovative technologies and social trends often determine the positive performance of an investment portfolio. The biggest challenge, however, is to recognize the development of a new need in society at the right time and to benefit from it with the right companies. But understanding what a problem is and who has a suitable solution to it is also crucial when making investment decisions on technologies. Nutrition, health and entertainment are industries of great social relevance. Significant innovations with adequate market access can ensure corresponding growth.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA1208311029 , CA29385B1094 , CA30207T1049

Table of contents:


    Natural proteins for nutrition

    Burcon Nutrascience, from Canada, focuses on the growth market of plant-based proteins. The company has established a pioneering role in the field of innovative technologies for the large-scale production of high-quality, cost-effective, plant-based ingredients. The products are used in the global food and beverage industry. Building on its environmentally friendly extraction and purification technologies, the company now holds an extensive portfolio of innovative composition, application and process patents, with over 280 patents and 260 patent applications pending.

    High-quality vegetable proteins, which are increasingly in demand by consumers worldwide, can be used in the future in convenience foods from well-known companies such as Nestle.

    Growth market natural active ingredients

    The young company EXMceuticals plans to position itself as a supplier of high-quality products and active ingredients in Europe. The operational team of the Canadian company is based in Lisbon, Portugal, and is preparing the expansion from there. The production of active ingredients from the cannabis plant for medical applications is the focus of the planning. The market for applications and therapies with natural ingredients is in a growth phase.

    In connection with the Corona Crisis, modern society had to learn painfully how big the dependence on China has become. It is quite bizarre that according to current knowledge the origin of COVID-19 is China and all drugs and protective clothing to stop its spread must also be obtained from China. It can be assumed that in the future, politics and economy will take a broader position in the procurement of critical and relevant products and ingredients and EXMceuticals will be able to profit from this development.

    On the tracks of the giants

    Enthusiast Gaming, as the largest community of its kind with now more than 200 million users per month, has the potential to follow in the footsteps of Alphabet, Amazon, Facebook and Netflix. Access to customers is critical to building a business model that ensures sustainable revenue streams. In addition to more than 900 YouTube channels, the company has seven Esports teams and has already passed the billion-dollar mark in views per month.

    For the future of the company, it is crucial to offer products and subscriptions that create added value for customers and at the same time convert customer loyalty into cash flow. Furthermore, Enthusiast Gaming offers an excellent advertising platform for companies that want to address gamers as a target group.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read